Navigation Links
Orexigen Therapeutics Prepares for the Light Study Interim Analysis Based on Direction from Data Monitoring Committee
Date:8/27/2013

An interim analysis and NDA resubmission is planned once the DMC has determined that sufficient information has been gathered for the analysis that would include at least 87 adjudicated MACE.

Orexigen has licensed North American commercial rights to Takeda Pharmaceuticals. Orexigen owns Contrave rights throughout the rest of the world and intends to license commercial rights outside North America.

About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase 3 clinical trials and for which a NDA has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a SPA for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

Forward‐Looking Statements
Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward‐looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward‐looking statements. These statements are based on the Company's current beliefs and expectations. These forward‐looking statements include statements regarding: the potential for, and timing of, the interim analysis and submission of a Contrave NDA; the potential for, and timing of, the accrual and adjudication of MACE; the expected retention rate for patients in the Light Study; the probability of success of the Light Study; the possibility of resubmitting the Contrave NDA with the independent DMC report on the interim a
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Orexigen Therapeutics to Present at Upcoming Conferences
2. Orexigen CEO Michael Narachi Elected to PhRMA Board of Directors
3. Orexigen Therapeutics Commends the Campaign to End Obesitys Report on Long-term Returns of Obesity Prevention Policies
4. Orexigen Therapeutics Reports Financial Results for the First Quarter Ended March 31, 2013
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
6. Technical Study: Vertex Pharma Inc., Orexigen Therapeutics Inc., MAKO Surgical Corp., and Alere Inc.
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
9. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
10. Fate Therapeutics Strengthens Its iPSC Platform
11. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... and Queens, New York (PRWEB) October 02, 2014 ... is pleased to announce funding received to investigate ... in Alzheimer’s disease. A grant award from the ... on Aging (NIA), National Institutes of Health (NIH) ... Novel AD Therapeutics." The company also received a ...
(Date:10/2/2014)... California (PRWEB) October 02, 2014 ... Livermore National Laboratory (LLNL) a grant today to ... researchers to better understand how the brain works ... project is part of NIH's efforts to support ... Neurotechnologies) Initiative, a new research effort to revolutionize ...
(Date:10/2/2014)... and BRIDGEWATER, N.J. , Oct. 2, ... a leader in synthetic biology, and Amneal ... manufacturer by volume in the U.S., today announced ... (ECC) for a target active pharmaceutical ingredient (API).  ... of the collaboration is to develop a consistent, ...
(Date:10/1/2014)... 1, 2014  Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" ... and sale of high pressure-based sample preparation systems to ... been invited to present at the 2 nd ... , Poland.  The Conference will take place at the ... Richard T. Schumacher , President and CEO of PBI, ...
Breaking Biology Technology:Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 2Gismo Therapeutics Inc. Awarded Grants to Develop New Alzheimer's Disease Therapeutics 3NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 3NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 4Intrexon and Amneal Expand Relationship with Second Product Collaboration 2Intrexon and Amneal Expand Relationship with Second Product Collaboration 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 2Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 4
... Genetics ,™ Inc., an innovative molecular diagnostics company developing the ... it completed the initial closing of a $14 million Series ... OrbiMed Advisors , Safeguard Scientifics, Inc. (NYSE: ... Proceeds from this financing will be used to augment commercial ...
... Want a see-through cellphone you can wrap around your wrist? ... Rice University chemist James Tour, whose lab has developed transparent, ... Tour revealed today in a talk at the national ... Diego that the new type of memory could combine with ...
... Centrix, a Nevada-based biotech corporation, announced this week its development ... a term used in programming wearable TheraEX (TM) skin ... field that surrounds all life forms. When ... in its basic form, it embodies seven major layers powered ...
Cached Biology Technology:Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 2Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 3Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 4Good Start Genetics Announces $14M Series B Financing, Expands Senior Management Team 5AlphaBio Centrix, LLC Announces a New Discovery for Programming Energetic Patches 2
(Date:9/30/2014)... almost any aquatic environment on Earth, but when the ... pushed to the limit. The amount of time needed ... how different species cope in the future, reveals a ... published in the scientific journal Proceedings of the ... thanks to increasing levels of greenhouse gases in the ...
(Date:9/30/2014)... to know what goes wrong with your muscles because of ... what "normal" actually is. That,s where a new research report ... FASEB Journal comes in. In the report, a ... molecules that can help scientists "see" which genes are active ... found never-before-detected gene activity and that men have approximately 400 ...
(Date:9/30/2014)... (September 30, 2014) People who suffer from asthma ... to control their asthma besides properly taking medications and ... article in the Annals of Allergy, Asthma and ... of Allergy, Asthma and Immunology (ACAAI), asthma sufferers can ... lifestyle. The woman described in the Annals article improved ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Scientists identify which genes are active in muscles of men and women 2Asthma symptoms kicking up? Check your exposure to air pollution 2
... requirements of new names for algae, fungi and plants ... Melbourne in July 2011 initiated several important challenges to scientists, ... the Congress decisions, the open access journal PhytoKeys ... one each day for the first week of 2012, starting ...
... This release is available in German . ... this more often when kin or mates are present than ... evidence that they take the other group members, knowledge state ... Anthropology in Leipzig, Germany, and the University of St. Andrews, ...
... found that elderly people with higher levels of several vitamins ... performance on mental acuity tests and less of the brain ... produced just the opposite result. The study was among ... range of blood nutrient levels instead of basing findings on ...
Cached Biology News:Brave new world 2Brave new world 3I know something you don't know -- and I will tell you! 2Diet, nutrient levels linked to cognitive ability, brain shrinkage 2
BD IMag Anti-Mouse CD90.2 (Thy1.2) Particles-DM 2 x 109 cells...
Chicken polyclonal to YebU ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to amino acids 196-244 of E. coli YebU....
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
... Antibody to CRF The ... ovine CRF sequence that it ... fibres are found in the ... brain in colchicine treated 4% ...
Biology Products: